Get to know our clinical trials
Clinical trial to evaluate the safety and pharmacokinetics of xb002 in monotherapy and polytherapy in patients with solid tumors.
THE OBJECTIVE OF THIS STUDY IS TO DETERMINE THE DMT AND/OR RD TO FURTHER EVALUATE THE INTRAVENOUS (I.V.) ADMINISTRATION OF XB002 IN MONOTHERAPY AND POLYTHERAPY IN PATIENTS WITH ADVANCED MALIGNANCIES.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- STEP-UP AND DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF XB002 IN MONOTHERAPY AND POLYTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC INOPERABLE SOLID TUMORS.
- Code EudraCT: 2021-006543-10
- Protocol number: XB002-101
- Promoter: Exelixis, Inc.
- Molecule/Drug: xb002
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.